73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Novel cell 'switches' found to promote lung cancer growth, treatment resistance

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi

Novel cell 'switches' found to promote lung cancer growth, treatment resistance

by Melissa Rohman,Northwestern UniversitySCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette wi
Survival rates high for children, teens with melanoma

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El
MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor
First immunotherapy success for triple-negative breast cancer

First immunotherapy success for triple-negative breast cancer

byQueen Mary, University of LondonThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image created in 2014 by

First immunotherapy success for triple-negative breast cancer

byQueen Mary, University of LondonThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image created in 2014 by
Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom

Study identifies genetic cause for some brain tumors

Study identifies genetic cause for some brain tumorsby Olivia Dimmer,Northwestern UniversityMultiplex immunofluorescence staining and imaging using the COMET system platform on a human meningiom
Ultrasound-guided surgery could be quicker, less painful and more effective for treating early form of breast cancer

Ultrasound-guided surgery could be quicker, less painful and more effective for treating early form of breast cancer

by European Organisation for Research and Treatment of CancerAntonio Esgueva using IOUS to guide breast surgery. Credit: Antonio Esguega / EORTCUsing ultrasound to guide surgery for patients with duct

Ultrasound-guided surgery could be quicker, less painful and more effective for treating early form of breast cancer

by European Organisation for Research and Treatment of CancerAntonio Esgueva using IOUS to guide breast surgery. Credit: Antonio Esguega / EORTCUsing ultrasound to guide surgery for patients with duct
Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b
“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im

“The power of science”: HPV vaccine proven to dramatically reduce cervical cancer

byLilly Matson| Analysis3 November 2021Share this articleAlmost all cervical cancers are caused by the human papilloma virus (HPV), depicted above.After decades of research,the UK im
After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v
Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11